Clinical trials: sponsored by Fujian Cancer Hospital
Nasopharyngeal Carcinoma by AJCC V8 Stage
CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis.
- Trial name
- NCT06095154
- Testing
- CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
- Where
- China
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Esophagus Cancer
Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell Carcinoma
Tislelizumab in resectable esophageal squamous cell carcinoma
- Trial name
- NCT06692270
- Testing
- Tislelizumab
- Volunteers
- 20 people
- Sponsor
- Fujian Cancer Hospital
Gastric Cancer Stage IV
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab
The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.
- Trial name
- NCT05319639
- Testing
- Oxaliplatin, Levo-Leucovorin, 5-fluorouracil
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Fujian Cancer Hospital
Small Cell Lung Cancer Extensive Stage
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
To evaluate the efficacy and safety of apatinib combined with adebrelizumab and EC in the first-line treatment of extensive small cell lung cancer
- Trial name
- NCT06786312
- Testing
- Apatinib, Adebrelimab, Etoposide Injection
- Where
- 4 sites in China
- Volunteers
- 34 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer
The purpose of this study is to investigate whether reducing both the dose and the irradiated volume of cervical prophylactic irradiation in patients with nasopharyngeal cancer can maintain efficacy while decreasing toxicity.
- Trial name
- NCT06775756
- Testing
- IMRT with reduced-dose and reduced-volume cervical prophylactic irradiation
- Volunteers
- 474 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.
Exploring the efficacy and safety of fruquintinib combined with S-1 for second-line and beyond treatment in patients with advanced colorectal cancer.
- Trial name
- NCT06746545
- Testing
- Fruquintinib+S-1
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Biliary Tract Cancer
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
This is a single-arm, open-label, prospective clinical study aimed at observing and evaluating the efficacy and safety of surufatinib combined with immunotherapy and chemotherapy in the treatment of unresectable or metastatic…
- Trial name
- NCT06654947
- Testing
- Surufatinib+Toripalimab+GEMOX
- Volunteers
- 23 people
- Sponsor
- Fujian Cancer Hospital
Nasopharyngeal Carcinoma
Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma
The incidence of nasopharyngeal carcinomas (NPCs) is highly unbalanced around the globe, primarily concentrated in East and Southeast Asia.There is no well-conducted, larger randomized controlled trials (RCT) outlining a gold…
- Trial name
- NCT06572293
- Testing
- Nurse-led intervention
- Volunteers
- 250 people
- Sponsor
- Fujian Cancer Hospital
Extensive-Stage Small Cell Lung Cancer
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT06614621
- Testing
- Adebrelimab +Etoposide+Platinum-based drugs, Maintenance treatment period:
- Volunteers
- 43 people
- Sponsor
- Fujian Cancer Hospital
Advanced Triple Negative Breast Cancer
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer
This study is a single-arm,exploratory clinical study, to evaluate the effectiveness and safety of apatinib mesylate combined with albumin-bound paclitaxel for second-line treatment of advanced triple negative breast cancer.
- Trial name
- NCT05019690
- Testing
- Apatinib Mesylate, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer
Exploring the Efficacy, Safety and Cost-effectiveness Analysis of Cadonilimab in the Treatment of Cervical Cancer
Cadonilimab, a PD-1/CTLA-4 bi-specific antibody, is being developed by Akeso, Inc. for the treatment of a range of solid tumors, including cervical cancer, lung cancer, gastric/gastroesophageal junction cancer, liver cancer and…
- Trial name
- NCT06140589
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fujian Cancer Hospital
Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib…
- Trial name
- NCT06600841
- Testing
- Immunotherapy（Adebrelimab）
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Cancer
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis
- Trial name
- NCT05628610
- Testing
- Tislelizumab, Radiation, Paclitaxel
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma, SBRT
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in…
- Conditions
- Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor
- Trial name
- NCT06538935
- Testing
- adbelimumab, SBRT, apatinib
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Liver Metastases of Colorectal Cancer
Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective…
- Trial name
- NCT06490913
- Testing
- Capecitabine, oxaliplatin, Cetuximab
- Volunteers
- 33 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of different doses of radiotherapy combined with sintilimab in locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06468644
- Testing
- chemoradiotherapy （CRT）+sintilimab 1, CRT+sintilimab 2
- Volunteers
- 60 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of short-course radiotherapy combined with sintilimab in neoadjuvant treatment of stage III, locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06468670
- Testing
- sintilimab，programmed death 1 monoclonal antibody
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Squamous Cell Carcinoma
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
This study is aimed to evaluate the efficacy and safety of sintilimab combined with chemotherapy (docetaxel+cisplatin+5-fluorouracil, DCF) in neoadjuvant treatment of locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06463834
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer Recurrent
Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer
In order to improve the clinical effect and find a new safe and effective treatment model for advanced recurrent cervical cancer, this study explored the efficacy level safety of pemetrexed, carboplatin, recombinant human…
- Trial name
- NCT06455046
- Testing
- AK104, Recombinant Human Adenovirus 5 Injection
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Cervical Cancer
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
In recurrent advanced cervical cancer, patients were prone to drug resistance who have relapsed within prior platinum-based chemotherapy.
- Trial name
- NCT06455072
- Testing
- Nituzumab, Serplulimab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital